Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Trends in post-relapse survival in Hodgkin lymphoma

Talha Badar • 3 Jun 2020
EHA 2020
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Nivolumab

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses trends in post-relapse survival in classic Hodgkin lymphoma. Specifically discussed is the advent of novel agents such as brentuximab vedotin and the resulting improvements in outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Talha Badar

Blinatumomab vs inotuzumab ozogamicin for ALL 4:38
Blinatumomab vs inotuzumab ozogamicin for ALL
Talha Badar • 2 Jun 2020
The impact of immuno-oncology on ALL outcomes 2:12
The impact of immuno-oncology on ALL outcomes
Talha Badar • 2 Jun 2020

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals